KURA
Kura Oncology, Inc.Kura Oncology, Inc. reported revenue of $67.48M in its most recent fiscal year, up 25.2% on the year before. It kept -412.9% of that as net income, and generated -$70.70M of free cash flow. Figures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | 25.2% | 7.4% | 74 / 219 |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | Not reported | 7.6% | — |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | Not reported | 7.3% | — |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | Not reported | -33.3% | — |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | Not reported | 4.0% | — |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | Not reported | 3.8% | — |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | -152.8% | -7.9% | 45 / 51 |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | Not reported | 1.4% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | Not reported | 72.1% | — |
Operating margin Operating income as a share of revenue. | -449.9% | -34.2% | 140 / 163 |
Net margin Net income as a share of revenue. | -412.9% | -30.0% | 151 / 173 |
Free cash flow margin Free cash flow as a share of revenue. | -104.8% | -15.3% | 108 / 156 |
Return on equity Net income divided by shareholder equity. | -160.0% | -52.3% | 303 / 368 |
Return on assets Net income divided by total assets. | -37.7% | -37.6% | 211 / 419 |
Return on invested capital After-tax operating profit over debt plus equity less cash. | -690.3% | -49.3% | 252 / 257 |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | 0.06x | 0.24x | 27 / 108 |
Current ratio Current assets over current liabilities. | 6.06x | 4.17x | 155 / 419 |
Quick ratio Current assets excluding inventory, over current liabilities. | 6.05x | 3.84x | 153 / 419 |
Interest coverage Operating income divided by interest expense. | -200.81x | -15.21x | 142 / 158 |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.56x | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Debt figures can be understated where a filer splits borrowings across XBRL tags this site does not match.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. 2 of the last 17 reported transactions were open-market purchases; the rest are mostly sales and compensation.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 29, 2026 | Leoni Mollie Chief Medical Officer | Open-market sale | 28,802 | $10.75 | $309.6K |
| Sep 29, 2026 | Powl Brian T. Chief Commercial Officer | Open-market sale | 15,430 | $10.75 | $165.9K |
| Sep 29, 2026 | FORD KATHLEEN Chief Operating Officer | Open-market sale | 3,668 | $10.75 | $39.4K |
| Sep 28, 2026 | Leoni Mollie Chief Medical Officer | Open-market sale | 12,448 | $10.50 | $130.7K |
| Sep 28, 2026 | Powl Brian T. Chief Commercial Officer | Open-market sale | 9,020 | $10.50 | $94.7K |
| Sep 28, 2026 | Bair Teresa Brophy Chief Legal Officer | Open-market sale | 8,442 | $10.50 | $88.6K |
| Sep 28, 2026 | Powl Brian T. Chief Commercial Officer | Open-market sale | 8,000 | $10.56 | $84.5K |
| Sep 28, 2026 | FORD KATHLEEN Chief Operating Officer | Open-market sale | 6,906 | $10.50 | $72.5K |
| Sep 28, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Open-market sale | 4,607 | $10.50 | $48.4K |
| Sep 24, 2026 | Burrows Francis Chief Scientific Officer | Open-market sale | 20,726 | $10.83 | $224.5K |
| Sep 24, 2026 | Burrows Francis Chief Scientific Officer | Option exercise | 30,000 | $6.15 | $184.5K |
| Sep 24, 2026 | Burrows Francis Chief Scientific Officer | Option exercise(derivative) | 30,000 | $0.00 | $0.00 |
| Sep 8, 2026 | Fulk Jennifer Chief Financial Officer | Grant or award(derivative) | 450,000 | $0.00 | $0.00 |
| Aug 24, 2026 | WILSON TROY EDWARD President and CEO | Open-market purchase | 100,000 | $12.39 | $1.24M |
| Aug 21, 2026 | Powl Brian T. Chief Commercial Officer | Open-market sale | 4,345 | $11.89 | $51.7K |
| Aug 19, 2026 | Bair Teresa Brophy Chief Legal Officer | Open-market sale | 31,487 | $12.63 | $397.7K |
| Aug 17, 2026 | WILSON TROY EDWARD President and CEO | Open-market purchase | 100,000 | $11.12 | $1.11M |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.48M | $53.88M | $0.00 | — | — | — | — | — | — | — |
| Operating income | -$303.63M | -$193.19M | -$165.80M | -$139.87M | — | — | — | — | — | — |
| Net income | -$278.67M | -$173.98M | -$152.63M | -$135.84M | -$130.47M | -$89.63M | -$63.14M | -$60.45M | -$35.43M | -$27.56M |
| EPS (diluted) | -$3.18 | -$2.02 | -$2.08 | -$2.03 | -$1.97 | -$1.69 | -$1.51 | -$1.72 | -$1.52 | -$1.47 |
| Operating cash flow | -$64.06M | $134.32M | -$124.82M | -$110.06M | -$104.55M | -$69.83M | -$54.76M | -$48.66M | -$28.44M | -$25.35M |
| Capital expenditure | $6.64M | $472.0K | $168.0K | $626.0K | $1.15M | $2.17M | — | — | — | — |
| Free cash flow | -$70.70M | $133.84M | -$124.99M | -$110.69M | -$105.70M | -$72.00M | — | — | — | — |
| Total assets | $738.36M | $760.16M | $448.94M | $456.31M | $534.05M | $647.21M | $241.97M | $182.38M | $95.85M | $69.82M |
| Shareholder equity | $174.13M | $413.64M | $397.27M | $420.28M | $506.61M | $610.90M | $218.78M | $160.99M | $79.86M | $56.88M |
| Total debt | $9.71M | $9.52M | $9.33M | $9.16M | — | $7.25M | $7.50M | $7.50M | $7.10M | $7.32M |
| Cash | $149.10M | $224.46M | $37.32M | $51.80M | $90.67M | $325.49M | $26.14M | $16.12M | $11.43M | $9.72M |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Source
Figures come from Kura Oncology, Inc.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Mar 5, 2026. View filings on EDGAR.